A study, published in Mayo Clinic Proceedings, demonstrates that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
